- Home
- ASRT vs TLSA Comparison
ASRT vs TLSA Comparison
Compare ASRT & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- TLSA
- Stock Information
- Founded
- ASRT 1995
- TLSA 2013
- Country
- ASRT United States
- TLSA United Kingdom
- Employees
- ASRT N/A
- TLSA N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- TLSA Health Care
- Exchange
- ASRT Nasdaq
- TLSA Nasdaq
- Market Cap
- ASRT 79.1M
- TLSA 187.0M
- IPO Year
- ASRT 1997
- TLSA 2000
- Fundamental
- Price
- ASRT $0.97
- TLSA $1.78
- Analyst Decision
- ASRT Strong Buy
- TLSA
- Analyst Count
- ASRT 1
- TLSA 0
- Target Price
- ASRT $3.00
- TLSA N/A
- AVG Volume (30 Days)
- ASRT 283.1K
- TLSA 330.7K
- Earning Date
- ASRT 11-10-2025
- TLSA 05-06-2025
- Dividend Yield
- ASRT N/A
- TLSA N/A
- EPS Growth
- ASRT N/A
- TLSA N/A
- EPS
- ASRT N/A
- TLSA N/A
- Revenue
- ASRT $117,099,000.00
- TLSA N/A
- Revenue This Year
- ASRT N/A
- TLSA N/A
- Revenue Next Year
- ASRT $6.75
- TLSA N/A
- P/E Ratio
- ASRT N/A
- TLSA N/A
- Revenue Growth
- ASRT N/A
- TLSA N/A
- 52 Week Low
- ASRT $0.51
- TLSA $0.63
- 52 Week High
- ASRT $1.37
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- ASRT 78.53
- TLSA 49.08
- Support Level
- ASRT $0.79
- TLSA $1.63
- Resistance Level
- ASRT $0.83
- TLSA $1.88
- Average True Range (ATR)
- ASRT 0.04
- TLSA 0.16
- MACD
- ASRT 0.01
- TLSA -0.00
- Stochastic Oscillator
- ASRT 84.65
- TLSA 69.23
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.